格隆汇1月27日丨美好医疗(301363.SZ)在投资者互动平台表示，公司高度重视人工智能等前沿技术的发 展，AI在材料参数智能选型、检测、生产工艺优化、品质合规与品质管控等方面具有巨大潜力，是公 司提升研发效率与产品力的重要赋能方向。公司一直都在密切关注相关技术的最新成果，结合公司的应 用场景积极布局和实践，有效把握AI技术创新给行业和公司带来的发展机遇。 ...

格隆汇1月27日丨美好医疗(301363.SZ)在投资者互动平台表示，公司高度重视人工智能等前沿技术的发 展，AI在材料参数智能选型、检测、生产工艺优化、品质合规与品质管控等方面具有巨大潜力，是公 司提升研发效率与产品力的重要赋能方向。公司一直都在密切关注相关技术的最新成果，结合公司的应 用场景积极布局和实践，有效把握AI技术创新给行业和公司带来的发展机遇。 ...

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

1月26日，美好医疗跌5.46%，成交额5.96亿元。两融数据显示，当日美好医疗获融资买入额4868.64万 元，融资偿还5884.57万元，融资净买入-1015.93万元。截至1月26日，美好医疗融资融券余额合计3.21 亿元。 融资方面，美好医疗当日融资买入4868.64万元。当前融资余额3.19亿元，占流通市值的1.74%，融资余 额超过近一年90%分位水平，处于高位。 分红方面，美好医疗A股上市后累计派现2.93亿元。 机构持仓方面，截止2025年9月30日，美好医疗十大流通股东中，国泰聚信价值优势灵活配置混合A （000362）位居第二大流通股东，持股591.79万股，为新进股东。华宝中证医疗ETF（512170）位居第 三大流通股东，持股481.27万股，相比上期减少88.13万股。香港中央结算有限公司位居第五大流通股 东，持股371.34万股，相比上期增加71.48万股。国泰金牛创新成长混合（020010）位居第六大流通股 东，持股361.79万股，为新进股东。鹏华新兴产业混合A（206009）位居第七大流通股东，持股357.58 万股，相比上期增加6.30万股。博时医疗保健混合A（050026 ...

近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入4868.64万元，融资偿还5884.57万元，融资净偿 还1015.93万元。融券方面，融券卖出2400.0股，融券偿还1800.0股，融券余量5.08万股，融券余额 163.41万元。融资融券余额3.21亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月26日收盘，美好医疗(301363)报收于32.18元，下跌5.46%，换手率 4.83%，成交量18.03万手，成交额5.96亿元。 1月26日的资金流向数据方面，主力资金净流出7406.67万元，占总成交额12.43%，游资资金净流出 1831.57万元，占总成交额3.07%，散户资金净流入9238.24万元，占总成交额15.5%。 该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为24.57。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量 ...

董秘： 尊敬的投资者，您好！目前欧美等西方发达国家和地区仍然是全球高端医疗器械产品和品牌的 发源地和消费地，也是公司业务收入的主要来源，公司积极推进全球化布局，构建贴近客户的本地化服 务能力，增强供应链弹性，提升公司的全球竞争优势，欧洲的布局计划也在有序的推进中。感谢您的关 注。 董秘最新回复 投资者： 今年9月贵司人工耳蜗已是医保报销范围内产品，请评估下对公司人工耳蜗业务板块后续影响 董秘： 尊敬的投资者，您好！新生儿先天失聪的发病率约为2‰-3‰，国内市场是全球人工耳蜗的主要 需求市场，但是国内的人工耳蜗的市场渗透率处于较低水平。人工耳蜗被纳入医保报销范围，将减轻听 障儿童家庭的经济负担，是一项重大的民生利好，该政策将有效释放国内市场的实际需求，对全球人工 耳蜗产业链和市场长期利好。感谢您对公司的关注。 投资者： 今年9月开始贵司人工耳蜗已是医保报销范围内的产品，请评估下对公司人工耳蜗业务板块后 续的影响。 董秘： 尊敬的投资者，您好！新生儿先天失聪的发病率约为2‰-3‰，国内市场是全球人工耳蜗的主要 需求市场，但是国内的人工耳蜗的市场渗透率处于较低水平。人工耳蜗被纳入医保报销范围，将减轻听 障儿童家庭的 ...

（文章来源：证券日报） 证券日报网讯 1月26日，美好医疗在互动平台回答投资者提问时表示，目前欧美等西方发达国家和地区 仍然是全球高端医疗器械产品和品牌的发源地和消费地，也是公司业务收入的主要来源，公司积极推进 全球化布局，构建贴近客户的本地化服务能力，增强供应链弹性，提升公司的全球竞争优势，欧洲的布 局计划也在有序的推进中。 ...

狄耐克最新股东户数27686户，环比下降18.13%，筹码集中以来股价下跌5.53%，累计换手率为 97.82%。 进一步统计，有21只创业板股筹码呈连续集中的态势，相比之前各期，股东户数连续减少3期以上，股 东户数最多已连降7期。 鸿铭股份最新股东户数为3905户，连续减少7期，累计降幅为22.01%；安诺其最新股东户数为43995 户，连续减少7期，累计降幅为12.79%；*ST清研最新股东户数为3091户，连续减少6期，累计降幅为 15.20%。股东户数连降期间，从累计降幅看，浙江华远、智动力、恒帅股份等股东户数降幅最多，累 计降幅分别为30.55%、30.37%、27.12%。 294只创业板股公布截至1月20日最新股东户数，环比上期，股东户数下降的有160只，降幅超过一成的 有13只。 证券时报·数据宝统计显示，294只创业板股公布了1月20日股东户数，与上期（1月10日）比，股东户数 下降的有160只，其中股东户数降幅超一成的有13只。股东户数环比增长的有107只。 股东户数降幅最多的是美好医疗，截至1月20日最新股东户数为29576户，较1月10日下降30.08%，筹码 集中以来该股累计下跌9. ...

内容概要：无障碍产业是指为残疾人、老年人、伤病员、孕妇等群体提供人体功能改善、补偿、替代或 实施辅助性治疗的新兴业态。它涵盖了出行设备、康复辅具、智能穿戴、智能看护、无障碍旅游、无障 碍电影等软硬件产品的研发、设计、生产、流通与服务的完整产业链条，对推动社会无障碍环境建设、 促进特殊群体社会融入具有重要意义。随着人口老龄化加速和残障群体需求升级，无障碍产业已从单纯 的福利事业转变为具有巨大市场的经济增长点。2025年，我国无障碍产业市场规模从2020年的780亿元 增长至1400亿元，预计2026年我国无障碍产业市场规模有望增长至1630亿元。 上市企业：英科医疗(002367.SZ)、瑞尔特(002790.SZ)、伟思医疗(688580.SH)、翔宇医疗(688626.SH)、 康力电梯(002367.SZ)、信隆健康(002105.SZ)、科大讯飞（002230）、商汤-W（00020）、云知声 （09678.HK）、鱼跃医疗（002223）、可孚医疗（301087）、美好医疗（301363）、上海建工 （600170）、中国铁建（601186）、万 科Ａ（000002）、亚厦股份（002375） 相关企 ...